Ramm Pharma (RAMM) AI Stock Analysis

• Market Cap: C$1.19M
• Dividend Yield: N/A
• Average Volume (3M): 638.00
• Price to Earnings (P/E): ―
• Beta (1Y): 1.92
• Revenue Growth: -6.32%
• EPS Growth: -83.07%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.13
• Shares Outstanding: 119,389,320
• 10 Day Avg. Volume: 1,916
• 30 Day Avg. Volume: 638
• PEG Ratio: -0.02
• Price to Book (P/B): 0.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Ramm Pharma's stock is weighed down by significant financial struggles, including persistent net losses and negative cash flows. Technical analysis further reflects weak momentum and bearish market conditions. The valuation is unattractive due to a negative P/E ratio and absence of dividends. Strategic improvements in financial performance are essential to enhance stock value.

Ramm Pharma Business Overview & Revenue Model

Company Description

Ramm Pharma (RAMM) is a company that operates in the pharmaceutical industry, focusing on the development and commercialization of cannabinoid-based pharmaceutical products. The company is involved in the research, production, and distribution of medical cannabis products for various therapeutic applications. Ramm Pharma aims to leverage its expertise in cannabinoid formulations to address a range of medical conditions, providing innovative and effective treatment options.

How the Company Makes Money

Ramm Pharma makes money primarily through the sale of its cannabinoid-based pharmaceutical products. The company's revenue model is centered around the production and distribution of medical cannabis products, which are sold to healthcare providers, pharmacies, and directly to patients in markets where medical cannabis is legal. Ramm Pharma may also engage in strategic partnerships and collaborations with other companies in the pharmaceutical and healthcare sectors to expand its product offerings and market reach. Additionally, the company may earn revenue from licensing its proprietary formulations and technologies to other entities in the industry.

Ramm Pharma Financial Statement Overview

Summary

Ramm Pharma faces significant financial challenges, characterized by persistent losses and negative cash flows. While the balance sheet reflects low leverage, operational inefficiencies and declining revenues pose risks to the company's financial health. Strategic improvements in cost management and revenue growth are critical for future sustainability.

Income Statement

Ramm Pharma has consistently reported negative net income, indicating ongoing profitability challenges. The net profit margin remains negative, and the company has faced declining revenues over the past periods. This highlights issues with cost control and revenue generation.

Balance Sheet

The company's balance sheet shows a reasonable debt-to-equity ratio, suggesting a low level of financial leverage. However, the declining equity base and significant losses impact the overall stability. The equity ratio is high, reflecting a strong reliance on equity, but may deteriorate if losses continue.

Cash Flow

Operating cash flow is consistently negative, indicating challenges in generating cash from core operations. Free cash flow has also been negative, impacting the company's ability to invest or pay down debt. The free cash flow to net income ratio is concerning, as it suggests poor cash conversion.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
4.40M	4.34M	5.07M	3.90M	4.12M	5.44M
	Gross Profit
1.44M	1.76M	381.82K	530.50K	-7.64K	1.28M
	EBIT
-6.50M	-6.76M	-7.09M	-7.93M	-7.19M	-7.58M
	EBITDA
-14.13M	-15.23M	-6.30M	-19.91M	-6.36M	-6.91M
	Net Income Common Stockholders
-15.23M	-16.50M	-7.72M	-20.96M	-7.11M	-7.43M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
480.44K	814.04K	5.12M	9.77M	17.16M	28.01M
	Total Assets
15.55M	16.75M	32.30M	39.31M	59.71M	37.17M
	Total Debt
197.69K	188.31K	405.14K	683.70K	32.16K	100.43K
	Net Debt
-282.75K	-625.73K	-4.71M	-9.09M	-17.12M	-27.91M
	Total Liabilities
3.12M	3.11M	2.84M	3.72M	3.32M	1.34M
	Stockholders Equity
12.43M	13.63M	29.46M	35.59M	56.39M	35.84M
Cash Flow		Free Cash Flow
-3.10M	-4.05M	-4.45M	-6.08M	-4.25M	-4.80M
	Operating Cash Flow
-3.04M	-4.00M	-4.34M	-5.91M	-3.82M	-2.91M
	Investing Cash Flow
-132.71K	-47.43K	126.58K	-1.15M	-6.83M	-1.56M
	Financing Cash Flow
-264.87K	-258.23K	-409.97K	-353.77K	-190.33K	-2.91M

Ramm Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RAMM, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 0.21 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RAMM.

Ramm Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.19B	3.04	-44.64%	2.82%	16.45%	-0.53%
RAMM	41 Neutral	C$1.19M	―	-75.84%	―	-6.32%	-83.07%
OVAT	39 Underperform	C$1.14M	―	62.01%	―	35.35%	31.85%
PHRX	29 Underperform	C$1.07M	―	-405.57%	―	―	-2291.11%

Ramm Pharma Corporate Events

RAMM Pharma Explores Sale of Italian Subsidiary Canapar

RAMM Pharma Corp. is considering the sale of its subsidiary, Canapar Corp., and its facility in Italy as part of its strategy to streamline operations and focus on core businesses. This potential sale is aimed at enhancing shareholder value and ensuring long-term company sustainability. However, there is no guarantee that a sale will occur, and updates will be provided as the process progresses.